Abstract Library

#3057 Epidemiological Features of Patients with NeuroEndocrine Neoplasms (NENs): Preliminary Results of an Observational Study by the Hellenic Society of Medical Oncology (HeSMO)

Introduction: NENs are rare tumors and can grow in almost all tissues. Regardless histological, molecular and imaging characteristics that are indicative of the primary origin, a significant percentage remain of unknown primary.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Koumarianou A

Authors: Koumarianou A, Tsoukalas N, Syrigos K, Demiri S, Ziras N,

Keywords: NeuroEndocrine Neoplasms (NENs), epidemiological features, registry, diagnosis, Hellenic Society of Medical Oncology (HeSMO),

#2242 Diagnostic Utility of Ki-67 as a Mean to Predict the Uptake of Functional Imaging Modalities in Patients with Neuroendocrine Neoplasms

Introduction: Functional imaging with FDG-PET and somatostatin receptors scintigraphy (SRS), play a key role in the diagnosis, treatment and follow-up of patients with neuroendocrine neoplasms (NENs). The proliferative index, ki67, is a reliable pathological marker for grading.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Mavroeidi V

Authors: Liotsou T, Mavroeidi V, Alexandraki K, Stefanoyiannis A, Thomas D,

Keywords: SRS, PET-FDG, ki-67, NENs,

#2060 Peptide Receptor Radionuclide Therapy (PRRT) in 35 Patients with Metastatic Neuroendocrine Neoplasms (NENs): Overall Response and Toxicity

Introduction: Metastatic or inoperable NeuroEndocrine Neoplasms (NENs) are unresponsive to chemotherapy and targeted therapies. An emerging option is PRRT.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Liotsou T

Authors: Liotsou T, Stefanoyiannis A, Alexandraki K, Koumarianou A, Angelousi A,

Keywords: NENs, PRRT,

#1935 Prevalence of Pancreatic Neuroendocrine Neoplasms with Serotonin Secretion

Introduction: Pancreatic neuroendocrine neoplasms (pNENs) are rare neoplasms and represent 1-2% of all pancreatic neoplasms. These tumors can secrete a variety of hormonally active substances producing distinct clinical symptoms, or can be clinically non-functioning. Pancreatic NENs that secrete serotonin are extremely rare, but their prevalence has not been explored adequately.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Tsoukalas N

Authors: Tsoukalas N, Alexandraki K, Mavroeidi V, Chatzellis E, Tsoli M,

Keywords: serotonin-producing pNEN, 5-HIAA, prognosis,

#1764 Use of Tyrosine-Kinase Inhibitors in Medullary Thyroid Carcinoma: An Institutional Experience

Introduction: Medullary thyroid cancer (MTC) comprises 4% of thyroid tumors. 7-23% of patients (pts) have metastases at diagnosis. In some cases metastatic disease follows an indolent course, and in others it progresses rapidly, requiring systemic treatment. Tyrosine-kinase inhibitors (TKI) have demonstrated a median progression-free survival (PFS) of 11 months.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Luca R

Authors: Luca R, O'Connor J, Falco A, Do Pico F, Tsou F,

Keywords: TNE, TKI,